Compugen traded at 584.10 this Thursday May 26th, decreasing 2.00 or 0.34 percent since the previous trading session. Looking back, over the last four weeks, Compugen lost 27.09 percent. Over the last 12 months, its price fell by 75.83 percent. Looking ahead, we forecast Compugen to be priced at 637.65 by the end of this quarter and at 591.01 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Clal Biotechnology 91.60 0 0% -59.88%
Compugen 584.10 -2.00 -0.34% -75.83%

Indexes Price Day Year
TA-125 1939 48.38 2.56% 9.28%

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.